Introduction
============

Pharmacogenomics aims to elucidate the contribution of genetic variants to interindividual variability in drug responses, such as efficacy, dose requirements and adverse reactions. Candidate gene association studies have been performed to assess the effects of single polymorphisms or haplotypes, the combination of alleles at multiple polymorphisms, on drug response phenotypes. In the past decade, genome-wide association studies (GWAS) in pharmacogenomics have led to the identification of variants associated with efficacy and adverse drug reactions. However, much of the genetic heritability to drug response phenotypes appears to be hidden in multigenic and multifactorial complex traits ([@B26]). It remains uncertain how many genes and genetic variants contribute to pharmacological traits, how common and rare variants affect response and whether gene--gene interactions play a role ([@B1]).

Gene--gene interactions among common regulatory variants can have strong effects in drug response phenotypes ([@B20]). Notably, findings from 108 GWAS in pharmacogenomics revealed that 96.4% of the 928 associated single nucleotide polymorphisms (SNPs) are located in non-coding regions ([@B4]). These findings suggest that most of common variants associated with variability in drug response are regulatory. However, most of the SNPs used in GWAS arrays were selected as informative genetic markers with higher allele frequencies and more likely to have greater power to detect association. In addition, the associated SNPs in GWAS are not necessarily the causal variant responsible for the phenotype, but may be in high linkage disequilibrium with the causal variant ([@B4]). Notably, the failure to replicate findings from pharmacogenetic studies, particularly in the analysis of single-locus, has prompted the search for novel statistical methods to analyze the data. These methods take into account the biological complexity underlying drug response and examine potential epistatic interactions that may predict drug response, as reviewed elsewhere ([@B13]; [@B18]).

The multifactorial nature of drug response phenotypes require novel approaches to detect complex genetic effects from multiple minor impact genes, entire pathways, gene--gene and gene-environment interactions ([@B26]). Therefore, research in pharmacogenomics should take into account the interactions among polymorphisms from different genes within drug response pathways. In this perspective article, we present current advances focused on gene--gene interactions associated with response to antihypertensive drugs, including non-coding SNPs found to be associated in GWAS and candidate gene studies, which are relevant to pharmacogenomics of hypertension and preeclampsia (**Figure [1](#F1){ref-type="fig"}**).

![**(A)** Interactions among Protein Kinase C Alpha (*PRKCA*), *NOS3*, and *BDKRB2* gene products within the ACE inhibitor pathway may affect the antihypertensive response to enalapril. Protein kinase C alpha (PKCα) upregulates the endothelial nitric oxide synthase (eNOS) activity, leading to enhanced nitric oxide (NO) production and vasodilation. Moreover, stimulating bradykinin receptors on endothelial cells may result in eNOS upregulation mediated by PKCα. **(B)** Interactions among genes of the visfatin/NAMPT pathway and response to nifedipine in preeclampsia. *NAMPT* was associated with antihypertensive response in preeclampsia depending on *TIMP1* and *MMP2* genotypes. Nifedipine may affect circulating MMP levels in hypertension. Nifedipine and visfatin/NAMPT increase PI3K/Akt pathway and eNOS activity, resulting in enhanced NO production. Ang I, Angiotensin I; Ang II, Angiotensin II; AGTR1, Angiotensin II Receptor Type 1; KNG, Kininogen.](fphar-09-00168-g001){#F1}

Gene--Gene Interactions in Pharmacogenomics of Hypertension
===========================================================

Hypertension is the most prevalent modifiable risk factor for stroke and coronary heart disease, affects approximately 1 billion individuals worldwide and is a leading cause of cardiovascular mortality. GWAS have also improved the understanding on hypertension genetics, and provide evidence to suggest that much of the genetic influence on hypertension reside within non-coding elements and operate through gene--gene interactions ([@B17]). The polygenic nature of hypertension indicates that single loci may not be considered as relevant clinical target for all individuals ([@B17]). These findings highlight the importance of assessing the interactions among multiple loci when studying complex traits, including drug response phenotypes.

Antihypertensive therapy is associated with a significant reduction in mortality, and blood pressure (BP) is monitored in response to treatment and dosage adjusted on the basis of BP response and adverse effects. However, only about half of patients on antihypertensive therapy achieve BP control ([@B2]). Genetic variation may partially account for the interindividual variability in response to antihypertensive drugs. Candidate gene studies and GWAS have identified common genetic polymorphisms associated with response to antihypertensive drugs, as reviewed elsewhere ([@B3]; [@B2]; [@B11]). Although no examples have been sufficiently validated for clinical use, the available findings suggest promise and pharmacogenomics holds the potential to guide the personalized treatment for patients who are non-responsive to hypertensive drugs ([@B2]).

Hydrochlorothiazide is among the most commonly prescribed antihypertensive drugs. A GWAS found an intronic SNP (rs16960228, A/G) of the *PRKCA* gene encoding protein kinase C alpha (PKCα) to be associated with BP response to hydrochlorothiazide in two cohorts and replicated in other cohorts of European Americans ([@B24]). Systolic and diastolic BP responses were consistently greater in carriers of the GA+AA genotypes than in homozygote GG carriers across all study samples. The rs16960228 SNP was also associated with diastolic BP response to the β-blocker atenolol, with the opposite direction of effect, which may be explained by the different pharmacologic mechanisms compared to thiazide diuretics ([@B24]; [@B2]).

Angiotensin-converting enzyme inhibitors (ACEi) are also widely used to treat hypertension, including enalapril. The mechanism of action involves the reduction of angiotensin II formation, but a secondary mechanism is related to vasodilation produced by nitric oxide (NO) as a result of endothelial nitric oxide synthase (eNOS) activation. Both mechanisms seem to be affected by PKC signaling, as reviewed elsewhere ([@B16]) (**Figure [1A](#F1){ref-type="fig"}**). Recently, the rs16960228 SNP of *PRKCA* gene was also associated with BP responses in hypertensive patients classified as poor or good responders to enalapril. The GA+AA genotypes, and the A allele, were associated with worse responses to enalapril ([@B16]). Previous expression studies have shown that *PRKCA* expression was significantly higher among carriers of the GA+AA genotypes than among those with the GG genotype ([@B24]). It is possible that the GG genotype can enhance the responses to ACEi, which increase PKCα. Conversely, it seems reasonable to suggest that PKCα signaling could be less affected by ACEi in patients carrying the GA+AA genotypes, resulting in worse responses to these drugs. However, the molecular mechanisms supporting these suggestions remain to be proved ([@B16]).

Interactions among genes within the ACEi pathway might also influence the responses to enalapril. Polymorphisms of the bradykinin receptor B2 (*BDKRB2*) and nitric oxide synthase 3 (*NOS3*) genes were associated with the antihypertensive responses to enalapril ([@B23]; [@B15]). However, the CC genotype for the rs1799722 SNP (C-58T) in the promoter region of *BDKRB2* gene was not associated with the response to enalapril in single-locus analysis. Interestingly, the gene--gene interaction analysis showed that the CC genotype for the rs1799722 SNP was associated with response to enalapril depending on genotypes for the rs2070744 SNP (T-786C) in the promoter region of *NOS3* gene. The combination with the TT genotype was more frequent in poor responders, while the combination with TC genotype was more frequent in good responders ([@B23]). These findings are obscured when single *BDKRB2* genotypes alone are considered, and were found to be associated with drug response only when performing gene--gene interaction analysis.

Furthermore, interactions among *PRKCA*, *BDKRB2* and *NOS3* genes were also shown to affect the response to enalapril ([@B16]). In single-locus analysis, the GG genotype for the rs16960228 GWAS SNP of *PRKCA* gene was associated with better responses to enalapril. However, the combinations between *BDKRB2* and *NOS3* genes found to be associated with either poor responders or good responders to enalapril described above ([@B23]) were significant only when combined with the GG genotype for the rs16960228 SNP of *PRKCA* gene ([@B16]). PKCα increases the transcription of *NOS3* gene and upregulates eNOS activity, leading to enhanced NO production and vasodilation. Moreover, ACEi increases tissue bradykinin levels, stimulating bradykinin receptors on endothelial cells, which may result in *NOS3* upregulation mediated by PKCα, as reviewed elsewhere ([@B16]). These gene--gene interactions could affect eNOS activity and NO bioavailability (**Figure [1A](#F1){ref-type="fig"}**). Thus, to evaluate circulating nitrite levels (a marker of endogenous NO formation) and plasma eNOS activity may be a possible approach to clarify the underlying molecular mechanisms. In this regard, *NOS3* polymorphisms were shown to modify plasma and blood nitrite concentrations ([@B12]; [@B15]). However, further studies are needed to examine the effects of gene interactions within this pathway on circulating nitrite levels and eNOS activity in patients treated with ACEi ([@B16]). Taken together, these findings highlight the relevance of take into consideration gene--gene interaction analysis in pharmacogenomics of hypertension.

Gene--Gene Interactions in Pharmacogenomics of Preeclampsia
===========================================================

Preeclampsia is a major cause of maternal and perinatal morbidity and mortality, defined as pregnancy-induced hypertension and proteinuria after 20 weeks of gestation. It is a multisystem disorder that has implications for future maternal health, in particular an increased risk of cardiovascular disease. Preeclampsia is a complex genetic disorder, and it is probable that no single gene or variant will be identified as responsible for all cases of preeclampsia ([@B25]). This scenario highlights the need to focus on more than one candidate gene, and on interactions among polymorphisms of different genes rather than on the effect of single polymorphisms. Indeed, interactions among SNPs in candidate genes within pathways relevant to disease pathophysiology were associated with the susceptibility to preeclampsia ([@B10], [@B8], [@B9]).

Antihypertensive therapy in preeclampsia includes methyldopa, nifedipine, hydralazine, and labetalol. These antihypertensive drugs allow the prolongation of gestation, thereby decreasing fetal and maternal adverse outcomes. However, a large subgroup of pregnant with preeclampsia is non-responsive to antihypertensive therapy and is associated with the worst clinical parameters ([@B7]). The use of pharmacogenomics may maximize the treatment outcome by reducing maternal and fetal morbidity and mortality associated with preeclampsia, as well as reducing adverse events associated with pharmacological therapy ([@B25]). However, pharmacogenetics of antihypertensive therapy in preeclampsia was the scope of just a few studies, which examined the association of genetic polymorphisms with subgroups of patients who were responsive or non-responsive to antihypertensive therapy ([@B7]). Patients with preeclampsia were classified according to response to the initial drug of choice, methyldopa, and to the total antihypertensive therapy, including nifedipine and hydralazine, the latter used in cases of hypertensive crisis, according to the criteria of responsiveness reviewed elsewhere ([@B7]).

These pharmacogenetic studies included polymorphisms that modify the expression of candidate genes related to the pathophysiology of preeclampsia ([@B7]). Notably, endothelial dysfunction is associated with both hypertension and proteinuria. NO plays an important role in regulating endothelial function, and the eNOS enzyme is responsible for NO synthesis in the cardiovascular system. Reduced expression of eNOS consequently results in reduced NO bioavailability which plays a significant role in the endothelial dysfunction associated with preeclampsia ([@B22]). Therefore, eNOS is considered as a potential target for therapy for preeclampsia ([@B25]). Calcium channel blockers (including nifedipine) may improve endothelial function and restore NO bioavailability, which could produce its effects by enhancing NO formation, thus counteracting the impaired NO bioavailability in preeclampsia ([@B22]) (**Figure [1B](#F1){ref-type="fig"}**). Nifedipine was shown to increase PI3K/Akt pathway and to increase eNOS activity and expression, as reviewed elsewhere ([@B6]). Therefore, *NOS3* polymorphisms that modulate NO synthesis could also interfere with the response to nifedipine. Notably, polymorphisms and haplotypes of *NOS3* gene were associated with the disease ([@B14]) or with the responsive and non-responsive subgroups of patients with preeclampsia ([@B21]).

Drugs that target the systemic vascular dysfunction were proposed as potential therapies for preeclampsia. Visfatin, an adipokine also known as nicotinamide phosphorybosil transferase (NAMPT), is considered a potential biomarker for vascular endothelial dysfunction. Notably, visfatin/NAMPT was shown to increase the expression and activity of eNOS in human endothelial cells, leading to an enhanced production of NO, as reviewed elsewhere ([@B19]). Therefore, *NAMPT* polymorphisms that modulate visfatin/NAMPT levels could be evaluated as biomarkers for this pathway. Notably, the rs1319501 SNP (T-423C) in the promoter region and the rs3801266 SNP (A/G) in the intron 1 of *NAMPT* gene were shown to be associated with the susceptibility to preeclampsia ([@B5]), and to affect plasma visfatin/NAMPT levels in patients who were non-responsive to total antihypertensive therapy ([@B9]). The TC+CC genotypes of the rs1319501 SNP and the AG+GG genotypes of the rs3801266 SNP were associated with lower and higher visfatin/NAMPT levels, respectively ([@B9]). However, further research on the interplay among visfatin/NAMPT levels, NO bioavailability and the response to antihypertensive therapy in preeclampsia are needed ([@B9]).

Visfatin/NAMPT induces endothelial cell proliferation and migration mediated by signaling pathways relevant to preeclampsia. It enhances the levels and activation of matrix metalloproteinases (MMP)-2/9 while decreasing the levels of tissue inhibitor of metalloproteinases (TIMP)-1/2 ([@B19]). MMPs are endopeptidases that may interact with vasoactive peptides and contribute to the endothelial dysfunction in preeclampsia. Notably, the GG genotype, and the G allele, of the rs2070584 (T/G) SNP of *TIMP1* gene were associated with both the disease and with the patients with preeclampsia who were non-responsive to antihypertensive therapy ([@B8]). Conversely, SNPs of *MMP2* and *NAMPT* genes were not found to be associated with the responsiveness to antihypertensive therapy in preeclampsia, as reviewed elsewhere ([@B7]). Interestingly, gene--gene interaction analysis showed that the GG genotype for the rs2070584 SNP of *TIMP1* was associated with preeclampsia and with responsiveness to total antihypertensive therapy in preeclampsia depending on genotypes for the rs3801266 SNP (A/G) of *NAMPT* gene. The combination with the AA was more frequent in the responsive patients, while the combination with the AG genotype was more frequent in the non-responsive patients ([@B9]). These combinations were significant only when combined with the CC genotype of the rs2285053 SNP (C-735C) of *MMP2* gene. These findings are obscured when single *MMP2* and *NAMPT* genotypes alone are considered, as they were not associated with the responsiveness in the single-locus analysis. Therefore, they further highlight the importance of gene--gene interactions in the genetics ([@B10]) and pharmacogenetics of preeclampsia ([@B7],[@B9]). Notably, calcium channel blockers (like nifedipine) were shown to affect circulating MMP levels in essential hypertensive patients, as reviewed elsewhere ([@B7]). However, further research into the molecular mechanisms underlying the interactions among *NAMPT*, *TIMP1* and *MMP2* and their relationship with the response to antihypertensive therapy in preeclampsia is needed (**Figure [1B](#F1){ref-type="fig"}**).

Conclusion and Perspectives
===========================

Here, we present current findings related to gene--gene interactions on pharmacogenomics of hypertension ([@B23]; [@B16]) and preeclampsia ([@B8], [@B9]). Of note, the reported association findings should be replicated in different populations. Moreover, the molecular mechanisms supporting these gene--gene interactions remain to be proved. Regarding preeclampsia, plasma from non-responsive and responsive patients was shown to evoke different gene expression profiles in human umbilical vein endothelial cells (HUVEC). Notably, nifedipine and hydralazine may act by upregulate or downregulate genes found to be downregulated or upregulated in HUVEC incubated with plasma from non-responsive patients ([@B6]). The use of transcriptomics data holds promise for potential insights and implications to the pharmacogenomics of hypertension ([@B2]).

We expect that epigenomics research focused on the regulatory role of GWAS associated SNPs located in non-coding regions might provide a deeper understanding of pathways involved in the response to antihypertensive drugs. Notably, more than 96% of the associated SNPs from GWAS in pharmacogenomics reside in non-coding regions, which suggest these common variants are regulatory ([@B4]). In addition, gene--gene interactions among common regulatory variants can have strong effects in drug response phenotypes ([@B20]). Therefore, we further expect that gene--gene interaction analysis are more likely to be used for pharmacogenomics in the future.

Taken together, these efforts will guide further studies focused on gene--gene interactions within pathways relevant to antihypertensive drug response, which may enable the identification of novel pharmacogenomic biomarkers to guide personalized medicine for hypertension and preeclampsia.
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